Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17212001 | 0.82 | CA2 (0.50) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL3275216 | 0.81 | TDP1 (0.36) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL10117371 | 0.81 | TDP1 (0.50) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL17211116 | 0.79 | TDP1 (0.42) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL2089321 | 0.77 | TDP1 (0.41) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL27680256 | 0.77 | TDP1 (0.35) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL4449244 | 0.75 | TDP1 (0.36) | TDP1KMT2AMEN1GAACA2 | |
| SCHEMBL14152450 | 0.75 | TDP1 (0.36) | TDP1KMT2AMEN1GAACA2 | |
| SCHEMBL20543014 | 0.75 | TDP1 (0.54) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL19995511 | 0.75 | TDP1 (0.50) | TDP1MAOAMAOBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | disclosed |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2024-10-15 | — | — | US | disclosed |
| EP-4215512-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| EP-3508468-B1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11059798-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200131143-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
| EP-3508468-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2019-07-10 | — | — | EP | disclosed |
| US-20190031631-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2019-01-31 | — | — | US | disclosed |
| US-10118907-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2018-11-06 | — | — | US | disclosed |
| US-20120322811-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-2392561-A1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | RHEOGENE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059798-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | TDP1 350/4885MAOA 2244/4885MAOB 1526/4885 |
| US-20120322811-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | TDP1 3408/4885MAOA 280/4885MAOB 232/4885 |
| US-20200131143-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | ESRRB, ESRRA, KDELR1 | TDP1 3788/4885MAOA 4519/4885MAOB 4364/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | TDP1 1055/4885MAOA 2048/4885MAOB 1270/4885 |
| US-20190031631-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | TDP1 3788/4885MAOA 4519/4885MAOB 4364/4885 |
| US-10118907-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | TDP1 3788/4885MAOA 4519/4885MAOB 4364/4885 |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | TDP1 3365/4885MAOA 325/4885MAOB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.